Tumour heterogeneity and a long-standing paucity of effective therapies other than
chemotherapy have contributed to triple-negative breast cancer (TNBC) being the subtype …

Simple Summary Triple negative breast cancer (TNBC) represents 15 to 20% of all breast
cancers in the United States. The main treatment option remains chemotherapy, despite …

Talazoparib, a PARP inhibitor, is active in germline BRCA1 and BRCA2 (g BRCA1/2)-mutant
advanced breast cancer, but its activity beyond g BRCA1/2 is poorly understood. We …

As the field of translational 'omics has progressed, refined classifiers at both genomic and
proteomic levels have emerged to decipher the heterogeneity of breast cancer in a clinically …

PARP inhibitors have been approved for the treatment of metastatic breast cancer in
germline BRCA mutation (g BRCA m) carriers. The recent OlympiA trial demonstrated …

Metastatic triple negative breast cancer (TNBC) has an aggressive phenotype with a
predilection for visceral organs and brain. Best responses to chemotherapy are …

Triple-negative breast cancer (TNBC) is a heterogeneous group of tumors characterized by
aggressive behavior, high risk of distant recurrence, and poor survival. Chemotherapy is still …

Due to the lack of definitive hormone receptors, triple negative breast cancer (TNBC)
patients receive little clinical benefit from endocrine or molecular targeted therapies, leading …

Triple-negative breast cancer (TNBC) is a clinically aggressive subtype of breast cancer that
represents 15–20% of breast tumors and is more prevalent in young pre-menopausal …

Triple‐negative breast cancer (TNBC) remains a major challenge in breast cancer
management. Continuing research in the past years aimed at understanding the biology of …